Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Protagonist Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Protagonist Therapeutics serves customers worldwide.
Website: protagonist-inc.com


  • Bad financial results growth rate -25.0% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (26.8%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -4.0% (LTM)
  • Share price is 712.3% higher than minimum and 17.4% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $26.6 mln (-0.374% of cap.)

Key Financials (Download financials)

Ticker: PTGX
Share price, USD:  (-2.6%)130.95
year average price 112.23  


year start price 84.61 2025-11-16

min close price 79.73 2026-01-29

max close price 158.62 2026-08-17

current price 130.95 2026-11-15
Common stocks: 49 042 232

Dividend Yield:  0.0%
EV / Sales: 137.1x
Margin (EBITDA LTM / Revenue): -280.4%

Target EV / EBITDA (hist percentile): 30.0x
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 6 422
Net Debt ($m): -115
EV (Enterprise Value): 6 307
EBITDA LTM (млн $): -129
Price to Book: 10.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-01fool.com

Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes

2026-01-13seekingalpha.com

Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-10-10fool.com

Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today

2025-09-11seekingalpha.com

Protagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

2025-09-03seekingalpha.com

Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference Transcript

2025-06-01businesswire.com

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

2025-05-06zacks.com

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

2025-03-25zacks.com

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

2025-03-03businesswire.com

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

2025-02-21zacks.com

Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-06 2024-11-07 2024-08-06 2024-05-07 2023-11-02 2023-08-03 2023-05-04 2022-11-08
acceptedDate 2025-11-06 16:52:09 2025-08-06 16:22:14 2025-02-21 16:36:59 2024-11-07 16:39:59 2024-08-06 16:18:39 2024-05-07 16:51:57 2024-02-27 16:33:25 2023-11-02 17:07:57 2023-08-03 16:21:30 2023-05-04 16:33:52 2023-03-15 16:46:42 2022-11-08 16:57:13 2022-02-28 16:50:37 2021-03-10 16:31:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 5M 6M 434M 5M 4M 255M 60M 0 0 0 27M 0 27M 29M
costOfRevenue 0 0 0 0 892 000 820 000 0 827 000 821 000 0 0 0 0 0
grossProfit 5M 6M 434M 5M 3M 254M 60M -827 000 -821 000 0 27M 0 27M 29M
grossProfitRatio 1 1 1 0.786 0.997 0 0 0 0
researchAndDevelopmentExpenses 40M 37M 138M 36M 34M 34M 120M 31M 33M 27M 126M 25M 126M 76M
generalAndAdministrativeExpenses 11M 11M 43M 10M 9M 15M 33M 8M 9M 9M 32M 7M 27M 19M
sellingAndMarketingExpenses 0 0 0 0 -892 000 -820 000 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 11M 11M 43M 10M 9M 14M 33M 8M 9M 9M 32M 7M 27M 19M
otherExpenses 0 0 0 0 97 000 -19 000 0 -31 000 -19 000 -195 000 0 0 0 -1M
operatingExpenses 51M 48M 182M 46M 42M 48M 154M 38M 42M 36M 158M 32M 153M 93M
costAndExpenses 51M 48M 182M 46M 43M 49M 154M 38M 42M 36M 158M 32M 153M 93M
interestIncome 7M 7M 26M 8M 7M 4M 15M 4M 4M 2M 4M 1M 443 000 900 000
interestExpense 0 0 0 0 0 0 0 0 0 -2M 0 -1M 0 598 000
depreciationAndAmortization 361 000 304 000 826 000 647 000 892 000 820 000 3M 827 000 821 000 832 000 3M 853 000 3M 948 000
ebitda -39M -42M 254M -41M -39M 207M -90M -38M -42M -36M -128M -31M -123M -64M
ebitdaratio -8.272 -7.526 -8.729 -9.096 0.812 0 0 0 0
operatingIncome -46M -42M 253M -41M -39M 206M -94M -38M -42M -36M -131M -32M -126M -65M
operatingIncomeRatio -9.852 -7.58 -8.867 -9.31 0.809 0 0 0 0
totalOtherIncomeExpensesNet 7M 7M 27M 8M 8M 4M 15M 4M -19 000 2M 4M 1M 294 000 -329 000
incomeBeforeTax -39M -35M 279M -34M -31M 211M -79M -34M -38M -34M -127M -31M -126M -65M
incomeBeforeTaxRatio -8.349 -6.239 -7.194 -7.509 0.826 0 0 0 0
incomeTaxExpense 0 172 000 4M -420 000 -676 000 3M 0 -827 000 -4M -2M 0 -1M 0 1M
netIncome -39M -35M 275M -33M -31M 207M -79M -34M -38M -31M -127M -30M -126M -66M
netIncomeRatio -8.349 -6.27 -7.104 -7.347 0.813 0 0 0 0
eps -0.62 -0.55 4.47 -0.54 -0.5 3.41 -1.39 -0.58 -0.68 -0.62 -2.52 -0.61 -2.65 -1.92
epsdiluted -0.62 -0.55 -0.54 -0.5 3.26 -0.58 -0.68 -0.62 -0.61
weightedAverageShsOut 64M 64M 62M 62M 61M 61M 57M 59M 57M 51M 49M 49M 46M 34M
weightedAverageShsOutDil 64M 64M 65M 62M 61M 64M 57M 59M 57M 51M 49M 49M 46M 34M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-21 2024-02-27 2023-03-15 2022-02-28 2021-03-10
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 26M 15M 4M 443 000 302 000
ebit 253M -94M -131M -126M -65M
nonOperatingIncomeExcludingInterest 0 0 0 0 0
netIncomeFromContinuingOperations 275M -79M -127M -126M -66M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 275M -79M -127M -126M -66M
epsDiluted 4.23 -1.39 -2.52 -2.65 -1.92

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-06 2024-11-07 2024-08-06 2024-05-07 2023-11-02 2023-08-03 2023-05-04 2022-11-08
acceptedDate 2025-11-06 16:52:09 2025-08-06 16:22:14 2025-02-21 16:36:59 2024-11-07 16:39:59 2024-08-06 16:18:39 2024-05-07 16:51:57 2024-02-27 16:33:25 2023-11-02 17:07:57 2023-08-03 16:21:30 2023-05-04 16:33:52 2023-03-15 16:46:42 2022-11-08 16:57:13 2022-02-28 16:50:37 2021-03-10 16:31:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 114M 169M 97M 131M 356M 173M 187M 231M 235M 128M 126M 153M 124M 117M
shortTermInvestments 462M 402M 322M 338M 208M 150M 155M 90M 78M 103M 112M 115M 203M 188M
cashAndShortTermInvestments 576M 570M 419M 469M 564M 323M 342M 323M 313M 231M 237M 267M 327M 306M
netReceivables 583 000 28M 168M 3M 1M 300M 10M 65 000 50 000 51 000 52 000 620 000 5M 4M
inventory 0 0 0 0 1 0 0 -2M -50 000 -51 000 0 0 0 0
otherCurrentAssets 10M 4M 0 5M 6M 5M 0 4M 4M 5M 0 9M 0 10000
totalCurrentAssets 586M 603M 592M 477M 571M 628M 356M 325M 317M 236M 243M 277M 341M 316M
propertyPlantEquipmentNet 12M 13M 13M 12M 12M 1M 2M 3M 3M 4M 5M 5M 7M 6M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 103M 102M 140M 0 32M 225 000 0 2M 225 000 0 0 0 0 2M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 287 000 290 000 225 000 115M 0 -1 225 000 225 000 0 225 000 225 000 225 000 225 000 450 000
totalNonCurrentAssets 115M 115M 153M 127M 44M 2M 2M 5M 4M 4M 5M 6M 7M 9M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 702M 718M 745M 604M 615M 629M 358M 330M 320M 240M 248M 282M 348M 324M
accountPayables 6M 3M 2M 3M 4M 4M 772 000 1M 5M 4M 4M 5M 2M 3M
shortTermDebt 2M 2M 0 45 000 0 462 000 0 2M 2M 3M 0 2M 0 0
taxPayables 0 0 3M 1M 3M 3M 0 0 0 0 0 0 0 0
deferredRevenue 0 15M 19M 20M 20M 16M 0 3000 10000 22 000 69 000 32 000 3M 17M
otherCurrentLiabilities 37M 15M 24M 21M 15M 20M 7M 25M 19M 17M 5M 30M 7M 6M
totalCurrentLiabilities 45M 36M 47M 45M 42M 40M 21M 28M 26M 23M 31M 37M 44M 40M
longTermDebt 9M 9M 0 11M 11M 0 0 0 0 462 000 0 2M 0 0
deferredRevenueNonCurrent 0 0 0 0 21M 29M 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 -21M 0 221 000 0 0 0 0 0 0 0
otherNonCurrentLiabilities 3M 5M 12M 17M 0 -1 -221 000 0 0 0 0 -5M 0 121 000
totalNonCurrentLiabilities 11M 14M 22M 27M 32M 29M 0 0 0 462 000 1M 2M 4M 5M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 11M 11M 11M 11M 11M 462 000 1M 2M 2M 3M 4M 4M 6M 6M
totalLiabilities 56M 50M 69M 72M 73M 69M 21M 28M 26M 24M 32M 39M 48M 45M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 0 0 0 0
retainedEarnings -426M -387M -341M -472M -439M -408M -616M -643M -609M -570M -537M -503M -409M -284M
accumulatedOtherComprehensiveIncomeLoss 524 999 -15 000 -82 000 1M -249 000 -229 000 -105 000 -170 000 -198 000 -122 000 -359 000 -480 000 -299 000 28 000
othertotalStockholdersEquity 1 071M 1 055M 1 003M 981M 969M 169 000 903M 121 000 747M
totalStockholdersEquity 645M 668M 675M 532M 541M 560M 337M -643M 294M -570M 216M 244M 300M 280M
totalEquity 645M 668M 675M 532M 541M 560M 337M -643M 294M -570M 216M 244M 300M 280M
totalLiabilitiesAndStockholdersEquity 702M 718M 604M 615M 629M -615M 320M -547M 282M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 702M 718M 745M 604M 615M 629M 358M -615M 320M -547M 248M 282M 348M 324M
totalInvestments 565M 504M 462M 338M 240M 150M 155M 90M 78M 103M 112M 115M 203M 190M
totalDebt 11M 11M 11M 11M 11M 462 000 1M 2M 2M 3M 4M 4M 6M 6M
netDebt -103M -157M -86M -120M -345M -172M -186M -229M -233M -125M -122M -149M -118M -111M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-21 2024-02-27 2023-03-15 2022-02-28 2021-03-10
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 165M 10M 10000 2M 2M
otherReceivables 3M 332 000 42 000 4M 1M
prepaids 4M 4M 6M 9M 6M
totalPayables 4M 871 000 4M 2M 3M
otherPayables 3M 99 000 415 000 407 000 82 000
accruedExpenses 0 12M 20M 30M 12M
capitalLeaseObligationsCurrent 510 000 1M 3M 2M 1M
capitalLeaseObligationsNonCurrent 10M 0 1M 4M 5M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 016M 952M 753M 710M 563M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX PTGX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-06 2024-11-07 2024-08-06 2024-05-07 2023-11-02 2023-08-03 2023-05-04 2022-11-08
acceptedDate 2025-11-06 16:52:09 2025-08-06 16:22:14 2025-02-21 16:36:59 2024-11-07 16:39:59 2024-08-06 16:18:39 2024-05-07 16:51:57 2024-02-27 16:33:25 2023-11-02 17:07:57 2023-08-03 16:21:30 2023-05-04 16:33:52 2023-03-15 16:46:42 2022-11-08 16:57:13 2022-02-28 16:50:37 2021-03-10 16:31:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -39M -35M 275M -33M -31M 207M -79M -34M -38M -34M -127M -31M -126M -66M
depreciationAndAmortization 361 000 304 000 3M 647 000 892 000 820 000 3M 827 000 821 000 832 000 3M 853 000 3M 3M
deferredIncomeTax 0 0 0 0 0 0 0 -7M 0 0 0 0 0 1M
stockBasedCompensation 0 11M 38M 10M 9M 9M 29M 7M 8M 8M 24M 6M 16M 8M
changeInWorkingCapital 28M -4M -123M -48M 291M -243M -20M 908 000 4M -8M -8M -683 000 -3M -19M
accountsReceivables -583 000 538 000 -155M 43 000 300M -290M 0 39 000 12 000 0 4M 0 -915 000 3M
inventory 0 0 0 0 0 0 0 0 -12 000 0 -4M 0 915 000 -3M
accountsPayables 2M 375 000 842 000 -352 000 -201 000 3M -3M -3M 552 000 381 000 2M 3M -1M 309 000
otherWorkingCapital 26M -5M 32M -47M -9M 44M -17M 4M 3M -8M -10M -4M -2M -19M
otherNonCashItems 9M -1M -9M 42M -291M 297M -4M 6M -960 000 -1M -549 000 -89 000 2M 781 000
netCashProvidedByOperatingActivities -2M -29M 184M -28M 269M -27M -70M -27M -26M -34M -108M -25M -108M -72M
investmentsInPropertyPlantAndEquipment -88 000 -813 000 -1M -775 000 -28 000 -242 000 -609 000 -404 000 -176 000 -10000 -795 000 -162 000 -1M -471 000
acquisitionsNet 0 0 0 0 0 0 0 13M -26M 0 -91M 0 15M 90M
purchasesOfInvestments -161M -67M -622M -267M -175M -66M -191M -59M -6M -28M -215M -32M -287M -280M
salesMaturitiesOfInvestments 103M 123M 324M 59M 87M 72M 152M 46M 32M 38M 307M 90M 272M 190M
otherInvestingActivites 0 -5000 0 -88M 6M -13M 26M 0 0
netCashUsedForInvestingActivites -59M 55M -209M -88M 6M -14M 26M 10M 57M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 6M 3M -10M 3M 8M -78 000 108M 24M 15M
commonStockRepurchased 0 0 0 600 000 0 -600 000 0 0 -669 000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 12M 3M -600 000 35M 973 000 2M -14M
netCashUsedProvidedByFinancingActivities 6M 3M 12M 3M 7M 35M 108M 26M 680 000
effectOfForexChangesOnCash 3000 0 0 0 0 0 0 0 0 0 -90 000 -175 000 -126 000 175 000
netChangeInCash -55M 29M -89M -224M 183M -14M 61M -5M 108M 2M 2M 33M 6M 84M
cashAtEndOfPeriod 114M 169M 97M 131M 356M 173M 187M 231M 236M 128M 126M 153M 124M 118M
cashAtBeginningOfPeriod 169M 140M 187M 356M 173M 187M 126M 236M 128M 126M 124M 120M 118M 33M
operatingCashFlow -2M -29M 184M -28M 269M -27M -70M -27M -26M -34M -108M -25M -108M -72M
capitalExpenditure -88 000 -813 000 -1M -775 000 -28 000 -242 000 -609 000 -404 000 -176 000 -10000 -795 000 -162 000 -1M -471 000
freeCashFlow -2M -30M 183M -29M 269M -28M -71M -27M -26M -34M -109M -25M -109M -73M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-21 2024-02-27 2023-03-15 2022-02-28 2021-03-10
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 91M -15M -90M
netCashProvidedByInvestingActivities -299M -39M 91M -16M -91M
netDebtIssuance 0 0 0 0 -11M
longTermNetDebtIssuance 0 0 0 0 -11M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 26M 132M 15M 124M 255M
netCommonStockIssuance 26M 132M 15M 124M 255M
commonStockIssuance 26M 132M 15M 124M 255M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -600 000 38M 4M 6M 3M
netCashProvidedByFinancingActivities 26M 170M 19M 130M 248M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

Press-releases

Show financial reports only

2026-11-05 ET
Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-10-27 ET
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026
2026-09-08 ET
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
2026-09-02 ET
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
2026-08-28 ET
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
2026-08-18 ET
Protagonist Therapeutics Reports Granting of Inducement Awards
2026-08-05 20:05 ET
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-04 20:05 ET
Protagonist Therapeutics Reports Granting of Inducement Awards
2026-07-16 ET
Protagonist Therapeutics Reports Granting of Inducement Awards
2026-07-01 ET
Protagonist Therapeutics Reports Granting of Inducement Awards
2026-06-16 ET
Protagonist Therapeutics Reports Granting of Inducement Awards
2026-06-01 ET
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
2026-05-28 ET
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
2026-05-05 ET
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-04-28 13:05 ET
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
2026-04-16 20:05 ET
Protagonist Therapeutics Reports Granting of Inducement Awards
2026-03-28 ET
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
2026-03-18 ET
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
2026-03-02 ET
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
2026-02-25 ET
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-02-25 ET
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-02-24 ET
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
2026-01-07 ET
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
2025-11-27 ET
DELETED: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
2025-11-06 ET
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-03 ET
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
2025-10-27 ET
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
2025-10-07 ET
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
2025-09-17 ET
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
2025-09-15 ET
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
2025-09-11 ET
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
2025-08-26 ET
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
2025-08-25 ET
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
2025-08-06 ET
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-07-21 ET
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
2025-06-30 ET
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
2025-06-26 ET
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
2025-06-01 ET
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
2025-05-21 ET
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
2025-05-09 ET
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
2025-05-06 ET
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
2025-04-23 ET
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
2025-04-16 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2025-04-10 ET
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
2025-03-18 ET
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
2025-03-10 ET
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
2025-03-08 ET
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
2025-03-03 ET
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
2025-02-21 ET
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2025-01-29 ET
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
2025-01-06 ET
Protagonist Therapeutics Reports Granting of Inducement Awards
2024-12-19 ET
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
2024-12-09 ET
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
2024-11-22 ET
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
2024-11-21 ET
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
2024-11-19 ET
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
2024-11-18 ET
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
2024-11-07 ET
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2024-11-05 21:05 ET
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
2024-09-03 11:30 ET
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
2024-08-06 11:00 ET
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
2024-08-01 11:00 ET
Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
2024-07-31 13:15 ET
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
2024-07-22 11:00 ET
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
2024-06-14 07:00 ET
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
2024-05-31 11:30 ET
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
2024-05-14 20:05 ET
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
2024-05-07 20:10 ET
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
2024-05-07 20:05 ET
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-03-26 11:00 ET
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
2024-03-18 11:00 ET
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
2024-03-11 11:00 ET
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
2024-03-06 21:05 ET
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
2024-02-27 21:05 ET
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-02-21 22:00 ET
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
2024-02-20 21:05 ET
Protagonist Therapeutics Reports Granting of Inducement Awards
2024-02-07 22:00 ET
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
2024-01-31 21:05 ET
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
2024-01-29 12:30 ET
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
2024-01-03 12:30 ET
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-13 12:30 ET
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
2023-12-13 ET
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
2023-12-12 14:04 ET
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
2023-11-27 14:00 ET
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
2023-11-16 21:05 ET
Protagonist Therapeutics Reports Granting of Inducement Awards
2023-11-09 20:55 ET
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)
2023-11-02 13:05 ET
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting
2023-11-02 04:00 ET
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-01 17:49 ET
Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis
2023-11-01 11:30 ET
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
2023-11-01 ET
Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis
2023-10-30 20:05 ET
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
2023-10-09 11:00 ET
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
2023-10-03 20:05 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2023-09-05 11:30 ET
Protagonist Therapeutics to Present at Upcoming Investor Conferences
2023-08-16 20:05 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2023-08-09 11:00 ET
Protagonist Receives $34 Million from Warrant Exercises
2023-08-09 ET
Protagonist Receives $34 Million from Warrant Exercises
2023-08-03 20:05 ET
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-18 20:05 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2023-07-04 07:30 ET
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
2023-06-09 12:05 ET
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects o...
2023-06-06 11:30 ET
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
2023-06-01 20:01 ET
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
2023-05-12 11:00 ET
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113
2023-05-11 20:05 ET
Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference
2023-05-11 14:17 ET
Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association
2023-05-04 20:05 ET
Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update
2023-04-05 02:45 ET
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
2023-04-04 20:11 ET
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
2023-04-04 ET
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
2023-03-15 20:01 ET
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
2023-03-15 11:30 ET
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
2023-03-07 13:00 ET
Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis
2022-12-21 21:05 ET
Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-01 12:05 ET
Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit
2022-11-16 21:05 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2022-11-08 21:05 ET
Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022-11-03 13:16 ET
Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting
2022-11-02 20:05 ET
Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer
2022-09-20 21:53 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2022-08-04 20:05 ET
Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-07-19 11:00 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2022-06-01 20:05 ET
Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
2022-05-26 21:10 ET
Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
2022-05-04 20:05 ET
Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-04-25 20:25 ET
Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
2022-04-19 20:15 ET
Protagonist Therapeutics Reports Granting of Inducement Awards
2022-03-28 11:06 ET
Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer
2022-03-16 11:00 ET
Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis
2022-02-28 21:05 ET
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
2022-02-10 12:00 ET
Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2022-01-04 12:00 ET
/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
2021-12-12 14:30 ET
Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting
2021-12-03 12:00 ET
Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit
2021-12-02 21:05 ET
Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications
2021-11-15 12:00 ET
Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis
2021-11-11 12:00 ET
Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
2021-11-04 11:00 ET
Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting
2021-11-03 20:05 ET
Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
2021-10-26 11:00 ET
Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Collaboration with Janssen
2021-10-12 11:00 ET
Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit
2021-10-11 11:00 ET
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
2021-10-04 11:00 ET
Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting
2021-09-17 11:00 ET
Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program
2021-09-15 21:05 ET
Protagonist Therapeutics Reports Granting of Inducement Awards
2021-09-07 11:00 ET
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology
2021-08-10 12:05 ET
Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma
2021-08-04 20:05 ET
Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress
2021-07-28 20:05 ET
Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists
2021-06-30 20:27 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2021-06-18 20:05 ET
Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2021-06-16 01:07 ET
Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock
2021-06-14 21:00 ET
Protagonist Therapeutics Announces Proposed Public Offering of Common Stock
2021-06-11 11:00 ET
Protagonist Therapeutics Announces Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera
2021-06-07 11:06 ET
Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021
2021-06-03 11:00 ET
Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera
2021-05-24 11:00 ET
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232
2021-05-12 15:14 ET
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021
2021-05-04 20:01 ET
Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update
2021-05-03 21:47 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2021-04-27 11:00 ET
Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting
2021-03-22 20:01 ET
Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines Agency
2021-03-10 21:01 ET
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
2021-03-03 12:00 ET
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
2021-03-02 12:00 ET
Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference
2021-02-26 23:20 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2021-02-16 12:00 ET
Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference
2021-01-29 23:22 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2021-01-04 12:00 ET
Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-16 12:30 ET
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
2020-12-15 21:30 ET
Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2020-12-11 04:10 ET
Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
2020-12-10 12:30 ET
Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
2020-12-07 15:00 ET
Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories
2020-12-06 19:45 ET
Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
2020-12-02 12:00 ET
Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera
2020-12-01 21:30 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2020-11-30 12:00 ET
Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020
2020-11-25 12:00 ET
Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference
2020-11-11 21:30 ET
Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference
2020-11-04 21:54 ET
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
2020-11-04 15:20 ET
Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting
2020-10-30 22:27 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2020-10-29 20:30 ET
Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen
2020-10-21 11:00 ET
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera
2020-09-17 20:30 ET
Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020
2020-09-15 20:48 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2020-09-10 20:30 ET
Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
2020-09-02 20:30 ET
Protagonist Therapeutics to Host PTG-300 Opportunity Update Webinar
2020-08-13 20:30 ET
Protagonist Appoints Sarah O'Dowd to Board of Directors
2020-08-06 20:01 ET
Protagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
2020-06-18 03:07 ET
Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera
2020-06-16 22:05 ET
Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference
2020-06-04 11:00 ET
Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress
2020-05-28 11:00 ET
Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences
2020-05-12 04:57 ET
Protagonist Therapeutics, Inc. Announces Upsizing and Pricing of Underwritten Public Offering of 7,000,000 Shares of Common Stock
2020-05-11 10:59 ET
Protagonist Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Common Stock
2020-05-07 20:31 ET
Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
2020-05-07 20:30 ET
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
2020-05-04 11:00 ET
Protagonist Therapeutics to Announce First Quarter 2020 Financial Results and Provide Corporate and R&D Update
2020-04-16 00:35 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2020-03-10 20:01 ET
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
2020-03-02 21:30 ET
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results
2020-02-19 12:00 ET
Protagonist Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference in New York
2020-02-07 12:00 ET
Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn's and Colitis Organization (ECCO)
2020-01-07 12:00 ET
Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
2020-01-06 12:00 ET
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
2019-12-03 12:00 ET
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
2019-11-13 12:00 ET
Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences
2019-11-06 21:30 ET
Protagonist Therapeutics Reports Third Quarter 2019 Financial Results
2019-11-06 21:01 ET
Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease
2019-10-31 11:00 ET
Protagonist Therapeutics Secures Debt Facility for up to $50 Million
2019-10-30 20:49 ET
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera
2019-10-01 11:00 ET
Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting
2019-09-25 11:00 ET
Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2
2019-09-04 20:30 ET
Protagonist Therapeutics Reports Granting of Inducement Awards
2019-09-03 20:30 ET
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference
2019-08-07 11:00 ET
Protagonist Therapeutics Reports Second Quarter 2019 Financial Results
2019-08-01 20:30 ET
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
2019-07-16 20:05 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2019-06-18 20:30 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2019-06-17 11:00 ET
Protagonist Therapeutics to Present at the BMO 2019 Prescription for Success Healthcare Conference
2019-06-04 11:00 ET
Protagonist Therapeutics Reports Granting of Inducement Award
2019-05-29 20:30 ET
Protagonist Therapeutics Appoints Don Kalkofen as Chief Financial Officer
2019-05-14 11:00 ET
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study
2019-04-01 11:00 ET
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9

SEC forms

Show financial reports only

SEC form 10
2026-11-06 00:00 ET
Protagonist Therapeutics reported for 2026 q3
SEC form 8
2026-11-05 00:00 ET
Protagonist Therapeutics published news for 2026 q3
SEC form 8
2026-11-05 00:00 ET
Protagonist Therapeutics published news for 2026 q3
SEC form 10
2026-08-05 20:17 ET
Protagonist Therapeutics reported for 2026 q2
SEC form 8
2026-08-05 20:11 ET
Protagonist Therapeutics published news for 2026 q2
SEC form 8
2026-08-05 20:11 ET
Protagonist Therapeutics published news for 2026 q2
SEC form 8
2026-08-05 20:11 ET
Protagonist Therapeutics published news for 2026 q2
SEC form 10
2026-05-05 20:27 ET
Protagonist Therapeutics reported for 2026 q1
SEC form 8
2026-05-05 20:08 ET
Protagonist Therapeutics published news for 2026 q1
SEC form 8
2026-05-05 20:08 ET
Protagonist Therapeutics published news for 2026 q1
SEC form 10
2026-02-25 16:28 ET
Protagonist Therapeutics reported for 2025 q4
SEC form 8
2026-02-25 16:08 ET
Protagonist Therapeutics published news for 2025 q4
SEC form 8
2026-02-25 16:08 ET
Protagonist Therapeutics published news for 2025 q4
SEC form 8
2026-01-12 13:00 ET
Protagonist Therapeutics published news for 2025 q4
SEC form 8
2026-01-12 13:00 ET
Protagonist Therapeutics published news for 2025 q4
SEC form 10
2025-11-06 16:52 ET
Protagonist Therapeutics reported for 2025 q3
SEC form 8
2025-11-06 16:19 ET
Protagonist Therapeutics published news for 2025 q3
SEC form 8
2025-11-06 16:19 ET
Protagonist Therapeutics published news for 2025 q3
SEC form 10
2025-08-06 20:22 ET
Protagonist Therapeutics reported for 2025 q2
SEC form 8
2025-08-06 20:12 ET
Protagonist Therapeutics published news for 2025 q2
SEC form 8
2025-08-06 20:12 ET
Protagonist Therapeutics published news for 2025 q2
SEC form 10
2025-05-06 21:04 ET
Protagonist Therapeutics reported for 2025 q1
SEC form 8
2025-05-06 20:27 ET
Protagonist Therapeutics published news for 2025 q1
SEC form 8
2025-05-06 20:27 ET
Protagonist Therapeutics published news for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Protagonist Therapeutics reported for 2025 q1
SEC form 8
2025-03-11 21:17 ET
Protagonist Therapeutics published news for 2024 q4
SEC form 8
2025-03-11 21:17 ET
Protagonist Therapeutics published news for 2024 q4
SEC form 8
2025-03-11 21:17 ET
Protagonist Therapeutics published news for 2024 q4
SEC form 8
2025-03-10 12:17 ET
Protagonist Therapeutics published news for 2024 q4
SEC form 8
2025-03-10 12:17 ET
Protagonist Therapeutics published news for 2024 q4
SEC form 8
2025-03-10 12:17 ET
Protagonist Therapeutics published news for 2024 q4
SEC form 8
2025-03-03 13:18 ET
Protagonist Therapeutics published news for 2024 q4
SEC form 8
2025-03-03 13:18 ET
Protagonist Therapeutics published news for 2024 q4
SEC form 8
2025-03-03 13:18 ET
Protagonist Therapeutics published news for 2024 q4
SEC form 10
2025-02-21 16:36 ET
Protagonist Therapeutics reported for 2024 q4
SEC form 8
2025-02-21 07:07 ET
Protagonist Therapeutics published news for 2024 q4
SEC form 8
2025-02-21 07:07 ET
Protagonist Therapeutics published news for 2024 q4
SEC form 10
2025-02-21 00:00 ET
Protagonist Therapeutics reported for 2024 q4
SEC form 10
2024-11-07 16:39 ET
Protagonist Therapeutics reported for 2024 q3
SEC form 8
2024-11-07 16:09 ET
Protagonist Therapeutics published news for 2024 q3
SEC form 8
2024-11-07 16:09 ET
Protagonist Therapeutics published news for 2024 q3
SEC form 10
2024-08-06 16:18 ET
Protagonist Therapeutics reported for 2024 q2
SEC form 8
2024-08-06 07:08 ET
Protagonist Therapeutics published news for 2024 q2
SEC form 8
2024-08-06 07:08 ET
Protagonist Therapeutics published news for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Protagonist Therapeutics reported for 2024 q2
SEC form 10
2024-05-07 16:51 ET
Protagonist Therapeutics reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Protagonist Therapeutics reported for 2024 q1
SEC form 8
2024-05-07 00:00 ET
Protagonist Therapeutics published news for 2024 q1
SEC form 8
2024-05-07 00:00 ET
Protagonist Therapeutics published news for 2024 q1
SEC form 10
2024-02-27 16:33 ET
Protagonist Therapeutics reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Protagonist Therapeutics reported for 2023 q4
SEC form 8
2024-02-27 00:00 ET
Protagonist Therapeutics published news for 2023 q4
SEC form 8
2024-02-27 00:00 ET
Protagonist Therapeutics published news for 2023 q4
SEC form 10
2023-11-02 00:00 ET
Protagonist Therapeutics reported for 2023 q3
SEC form 8
2023-11-02 00:00 ET
Protagonist Therapeutics published news for 2023 q3
SEC form 10
2023-08-03 16:21 ET
Protagonist Therapeutics reported for 2023 q2
SEC form 6
2023-08-03 16:13 ET
Protagonist Therapeutics reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Protagonist Therapeutics reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Protagonist Therapeutics reported for 2023 q2
SEC form 6
2023-07-05 08:00 ET
Protagonist Therapeutics published news for 2023 q2
SEC form 6
2023-07-03 16:06 ET
Protagonist Therapeutics published news for 2023 q2
SEC form 10
2023-05-04 00:00 ET
Protagonist Therapeutics reported for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Protagonist Therapeutics reported for 2023 q1
SEC form 6
2023-04-12 16:02 ET
Protagonist Therapeutics published news for 2023 q1
SEC form 6
2023-04-10 09:00 ET
Protagonist Therapeutics published news for 2023 q1
SEC form 10
2023-03-15 16:46 ET
Protagonist Therapeutics reported for 2022 q4
SEC form 6
2023-03-15 16:11 ET
Protagonist Therapeutics reported for 2022 q4
SEC form 10
2023-03-15 00:00 ET
Protagonist Therapeutics reported for 2022 q4
SEC form 8
2023-03-15 00:00 ET
Protagonist Therapeutics reported for 2022 q4
SEC form 6
2023-03-10 15:36 ET
Protagonist Therapeutics published news for 2022 q4
SEC form 6
2023-01-18 20:13 ET
Protagonist Therapeutics published news for 2022 q4
SEC form 6
2023-01-18 20:10 ET
Protagonist Therapeutics published news for 2022 q4
SEC form 6
2023-01-18 20:03 ET
Protagonist Therapeutics published news for 2022 q4
SEC form 6
2023-01-18 20:00 ET
Protagonist Therapeutics published news for 2022 q4
SEC form 6
2023-01-18 19:58 ET
Protagonist Therapeutics published news for 2022 q4
SEC form 6
2023-01-06 16:30 ET
Protagonist Therapeutics published news for 2022 q4
SEC form 6
2022-11-17 18:24 ET
Protagonist Therapeutics published news for 2022 q3
SEC form 6
2022-11-17 18:20 ET
Protagonist Therapeutics published news for 2022 q3
SEC form 10
2022-11-08 16:57 ET
Protagonist Therapeutics reported for 2022 q3
SEC form 6
2022-11-08 16:11 ET
Protagonist Therapeutics reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Protagonist Therapeutics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Protagonist Therapeutics reported for 2022 q3
SEC form 10
2022-08-04 16:58 ET
Protagonist Therapeutics reported for 2022 q2
SEC form 6
2022-08-04 16:10 ET
Protagonist Therapeutics published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Protagonist Therapeutics reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Protagonist Therapeutics reported for 2022 q2
SEC form 6
2022-06-02 16:00 ET
Protagonist Therapeutics published news for 2022 q1
SEC form 10
2022-05-05 16:50 ET
Protagonist Therapeutics reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Protagonist Therapeutics reported for 2022 q1
SEC form 6
2022-05-04 20:41 ET
Protagonist Therapeutics published news for 2022 q1
SEC form 6
2022-05-04 17:18 ET
Protagonist Therapeutics published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Protagonist Therapeutics reported for 2022 q1
SEC form 6
2022-04-26 21:42 ET
Protagonist Therapeutics published news for 2022 q1
SEC form 6
2022-04-26 21:34 ET
Protagonist Therapeutics published news for 2022 q1
SEC form 6
2022-04-26 06:02 ET
Protagonist Therapeutics published news for 2022 q1
SEC form 6
2022-04-19 19:35 ET
Protagonist Therapeutics published news for 2022 q1
SEC form 6
2022-04-13 17:07 ET
Protagonist Therapeutics published news for 2022 q1
SEC form 6
2022-04-13 16:30 ET
Protagonist Therapeutics published news for 2022 q1
SEC form 6
2022-03-31 16:13 ET
Protagonist Therapeutics published news for 2021 q4
SEC form 6
2022-03-23 16:05 ET
Protagonist Therapeutics published news for 2021 q4
SEC form 10
2022-02-28 16:50 ET
Protagonist Therapeutics published news for 2021 q4
SEC form 6
2022-02-28 16:26 ET
Protagonist Therapeutics published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Protagonist Therapeutics published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Protagonist Therapeutics published news for 2021 q4
SEC form 6
2022-02-22 16:30 ET
Protagonist Therapeutics published news for 2021 q4
SEC form 10
2021-11-03 17:09 ET
Protagonist Therapeutics published news for 2021 q3
SEC form 6
2021-11-03 16:08 ET
Protagonist Therapeutics published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Protagonist Therapeutics published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
Protagonist Therapeutics published news for 2021 q3
SEC form 6
2021-09-17 17:29 ET
Protagonist Therapeutics published news for 2021 q2
SEC form 6
2021-08-10 08:00 ET
Protagonist Therapeutics published news for 2021 q2
SEC form 10
2021-08-04 16:40 ET
Protagonist Therapeutics published news for 2021 q2
SEC form 6
2021-08-04 16:13 ET
Protagonist Therapeutics published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Protagonist Therapeutics published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Protagonist Therapeutics published news for 2021 q2
SEC form 6
2021-07-28 16:10 ET
Protagonist Therapeutics published news for 2021 q2
SEC form 6
2021-06-17 16:57 ET
Protagonist Therapeutics published news for 2021 q1
SEC form 6
2021-06-14 16:52 ET
Protagonist Therapeutics published news for 2021 q1
SEC form 6
2021-05-28 17:16 ET
Protagonist Therapeutics published news for 2021 q1
SEC form 10
2021-05-04 16:55 ET
Protagonist Therapeutics published news for 2021 q1
SEC form 6
2021-05-04 16:07 ET
Protagonist Therapeutics published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Protagonist Therapeutics published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Protagonist Therapeutics published news for 2021 q1
SEC form 6
2021-04-14 16:08 ET
Protagonist Therapeutics published news for 2021 q1
SEC form 10
2021-03-10 16:31 ET
Protagonist Therapeutics published news for 2020 q4
SEC form 6
2021-03-10 16:04 ET
Protagonist Therapeutics published news for 2020 q4
SEC form 6
2020-12-11 06:30 ET
Protagonist Therapeutics published news for 2020 q3
SEC form 10
2020-11-04 17:21 ET
Protagonist Therapeutics published news for 2020 q3
SEC form 6
2020-11-04 17:12 ET
Protagonist Therapeutics published news for 2020 q3
SEC form 6
2020-10-02 17:13 ET
Protagonist Therapeutics published news for 2020 q3